康方生物:卡度尼利一线治疗宫颈癌亚组分析数据在ASCO 2025发布

人民财讯
16 Jun

  据康方生物消息,近日,康方生物自主研发的全球首创PD-1/CTLA-4双特异性抗体开坦尼®(卡度尼利单抗注射液)一线治疗持续、复发或转移性宫颈癌中的III期临床研究(COMPASSION-16)的亚组分析数据在2025年美国临床肿瘤学会年会(ASCO 2025)上以口头报告形式发表。

  研究亚组分析显示:无论PD-L1表达水平,既往是否接受同步放化疗(CCRT)、贝伐珠单抗使用情况以及年龄(≥65,<65)等情况,亚组分析结果与总体人群的结果一致,卡度尼利治疗方案均极大改善了PFS和OS,再度强化了卡度尼利方案完全迭代晚期宫颈癌标准治疗的巨大临床价值和商业化潜力。

(文章来源:人民财讯)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10